Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

OP used minoxidil for 15 months and pyrilutamide for 46 days, achieving desired results without side effects. Users discussed alternatives like dutasteride and finasteride, with concerns about side effects like erectile dysfunction.

The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

A user experienced severe chest pains and shortness of breath after using RU58841 for hair loss and was advised by a doctor that blocking androgens can weaken the heart. They decided to continue with finasteride, minoxidil, and a hair transplant instead.

Minoxidil may suppress androgen activity in hair follicles, potentially aiding in hair growth and prostate cancer treatment. Users discuss the effectiveness of minoxidil and finasteride for hair maintenance and regrowth, with some preferring topical applications over oral due to safety concerns.

The conversation is about the effectiveness of Minoxidil formulations with different alcohol and propylene glycol (pg) ratios. The user finds that a formulation with 20% pg and 80% ethanol dries faster but is concerned about absorption time.

Using RU58841 and topical minoxidil together is fine and does not cancel out the benefits of each. Applying both treatments consecutively is acceptable.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

Users discussed their experiences with minoxidil and finasteride for hair loss, sharing application methods and side effects. Concerns included hair texture changes, safety around pets, and the importance of consulting a doctor before using oral minoxidil.

The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.

RU58841 is more effective when mixed with isopropyl alcohol instead of minoxidil, as water in minoxidil degrades RU58841. Applying RU58841 separately from minoxidil, with an hour gap, enhances hair growth results.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.

The conversation is about the potential side effects of using verteporfin in conjunction with a hair transplant. Specific treatments discussed include verteporfin, a hair transplant (HT), minoxidil (Min), finasteride (Fin), and RU58841 (RU).

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

Hair loss discussion includes Latanoprost as potential treatment. Mild improvement observed with its use.

Minoxidil causes dryness, and adding an emollient might help. The foam version is suggested to reduce dryness.

PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hair follicles, potentially offering a long-term solution, though not a permanent cure.

Concerns about metal particles from dermapen or dermaroller needles potentially entering the skin and lymph nodes, similar to tattoo needles. Discussion includes the possibility of using Minoxidil, finasteride, and RU58841 for hair loss treatment.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

Pyrilutamide's effectiveness is questioned due to overstated claims and previous trial ineffectiveness, with some users opting for finasteride instead. Despite skepticism, some consider adding pyrilutamide to their regimen alongside treatments like bicalutamide.

A user is considering using 70% isopropyl alcohol with glycerin as a carrier for topical finasteride for hair loss but is concerned about its safety compared to ethanol. They are unsure where to buy ethanol without toxic methanol.

Hair loss research is important and contributes to overall scientific advancement, benefiting emotional well-being and potentially aiding other medical fields. Treatments mentioned include PP405 and SCUBE3.

The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Elevated PGD2 levels in bald scalp tissue may contribute to hair loss, and treatments like castor oil, finasteride, and minoxidil are discussed as potential solutions. Some users explore alternatives like oral castor oil and cetirizine for those who cannot use finasteride.

The user discusses their struggle with hair loss and inability to use Minoxidil or finasteride due to medical conditions. They are currently using Hairmetto gel and dermarolling, and are considering trying Breezula or Revivhair serum.